Exosens Shares Cross the 61 Euro Mark, Boosted by JP Morgan's Upgrade
Exosens saw a significant rise this Thursday, with its stock increasing by 2.69% to 61.10 euros. This advance follows a target price upgrade by JP Morgan, released today. The group, specializing in detection and amplification technologies, now records a performance of nearly 48% over three months.
Today's session was marked by a notable upward revision of JP Morgan's target price, which increased from 60 to 71 euros, while maintaining an 'overweight' recommendation. At the current price of 61.10 euros, this target implies a potential appreciation of about 16%. This significant increase reflects the American bank's enhanced confidence in the group's prospects. Yesterday, Deutsche Bank adjusted its target from 52 to 55 euros, with a 'hold' recommendation. This level is below the current price, suggesting a more measured view from the German institution. The disparity between the two evaluations highlights the diversity of analyses by research firms on Exosens's valuation trajectory.
Technical Analysis Insights
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the price of 61.10 euros is approaching the upper Bollinger band, set at 61.83 euros, indicating a short-term bullish tension zone. This level coincides with the breach of the resistance threshold identified at 60.50 euros, a significant technical milestone that could pave the way for further progression if the movement is confirmed in upcoming sessions. Additionally, the RSI stands at 66, which is below the overbought zone (generally set at 70), leaving some room before a potential bullish excess signal. The medium-term dynamics remain well-oriented: the stock is significantly above its 50-day moving average (53.48 euros) and its 200-day moving average (45.33 euros). The next key date on the financial calendar is the publication of the first-quarter results, scheduled for April 27, 2026.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
